Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02583438

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02583438
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02583438. Allocation not applicable; no masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2017-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
Condition
Obesity
Intervention (Drug)
Saxagliptin (Bristol-Myers Squibb Company)
Lead sponsor
Beijing Chao Yang Hospital (class: other)

Record details

Record id
cardio:ct-nct02583438
Content hash
3e51b60d02497d2e3caf90838ccae729433716559478743586bc5596a0a09195